Tumour-Derived Cell Lines and Their Potential for Therapy Prediction in Patients with Metastatic Colorectal Cancer

被引:8
|
作者
Wagner, Sandra [1 ]
Beger, Nicola T. [1 ]
Matschos, Stephanie [1 ]
Szymanski, Antonia [1 ]
Przybylla, Randy [1 ]
Buertin, Florian [1 ]
Prall, Friedrich [2 ]
Linnebacher, Michael [1 ]
Mullins, Christina S. [1 ]
机构
[1] Univ Med Rostock, Dept Gen Surg, Mol Oncol & Immunotherapy, D-18057 Rostock, Germany
[2] Univ Med Rostock, Inst Pathol, D-18057 Rostock, Germany
关键词
colorectal cancer; metastasis; chemosensitivity; therapy prediction; matching cell line pairs of primaries and metastases; CLINICAL PHARMACOKINETICS; 1ST-LINE TREATMENT; OXALIPLATIN; MUTATIONS; IRINOTECAN; FLUOROURACIL; FOLFOXIRI; CPT-11; COLON; P53;
D O I
10.3390/cancers13184717
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Colorectal cancer is a global issue with millions of patients in need for new treatment options. Surgical resection is often the first clinical intervention and can be, especially for primary tumours, curative. However, advanced tumours, recurrences, and metastases require drug treatment. Our aim was to compare material of primary tumours and corresponding metastases to draw conclusions from the first one to the latter. The feasibility of therapy prediction using the primary tumour material for the metastatic situation creates a time window for functional testing, which can realistically be integrated into the strict timeframe of clinical procedures. A reliable treatment recommendation, based on the tumour drug response, would improve treatment success in patients with metachronous metastases and spare them from unnecessary side effects of unsuccessful therapies. The prognosis of metastatic colorectal cancer (CRC) remains poor. Patients and physicians are in need of individual therapies and precise response predictions. We investigated the predictive capacity of primary tumour material for treatment response of metastases. Mutational landscapes of primary tumours and corresponding metastases of 10 CRC patients were compared. Cell line characteristics and chemosensitivity were investigated pairwise for primary and metastatic tumours of four patients. PDX models of one patient were treated in vivo for proof of concept. Driver mutations did not differ between primaries and metastases, while the latter accumulated additional mutations. In vitro chemosensitivity testing revealed no differences for responses to 5-FU and oxaliplatin between primary and metastatic cell lines. However, irinotecan response differed significantly: the majority of metastases-derived cell lines was less sensitive to irinotecan than their matching primary counterpart. Therapy recommendations based on these findings were compared to clinical treatment response and mostly in line with the predicted outcome. Therefore, primary tumour cell models seem to be a good tool for drug response testing and conclusion drawing for later metastases. With further data from tumour-derived cell models, such predictions could improve clinical treatment decisions, both recommending likely effective therapeutic options while excluding ineffective treatments.
引用
收藏
页数:16
相关论文
共 50 条
  • [1] Tumour-derived adhesion factor in colorectal cancer
    Malarstig, Anders
    Wagsater, Dick
    Lofgren, Sture
    Hugander, Anders
    Zar, Niklas
    Dimberg, Jan
    [J]. MOLECULAR MEDICINE REPORTS, 2009, 2 (06) : 971 - 976
  • [2] Circulating tumour-derived nucleic acids in cancer patients: potential applications as tumour markers
    K C A Chan
    Y M D Lo
    [J]. British Journal of Cancer, 2007, 96 : 681 - 685
  • [3] Circulating tumour-derived nucleic acids in cancer patients: potential applications as tumour markers
    Chan, K. C. A.
    Lo, Y. M. D.
    [J]. BRITISH JOURNAL OF CANCER, 2007, 96 (05) : 681 - 685
  • [4] Tumour-derived extracellular vesicles in blood of metastatic cancer patients associate with overall survival
    Afroditi Nanou
    M. Craig Miller
    Leonie L. Zeune
    Sanne de Wit
    Cornelis J. A. Punt
    Harry J. M. Groen
    Daniel F. Hayes
    Johann S. de Bono
    Leon W. M. M. Terstappen
    [J]. British Journal of Cancer, 2020, 122 : 801 - 811
  • [5] Tumour-derived extracellular vesicles in blood of metastatic cancer patients associate with overall survival
    Nanou, Afroditi
    Miller, M. Craig
    Zeune, Leonie L.
    de Wit, Sanne
    Punt, Cornelis J. A.
    Groen, Harry J. M.
    Hayes, Daniel F.
    de Bono, Johann S.
    Terstappen, Leon W. M. M.
    [J]. BRITISH JOURNAL OF CANCER, 2020, 122 (06) : 801 - 811
  • [6] A novel approach to detect tumour-derived DNA in plasma from patients with colorectal cancer
    Clark, AJ
    Farrington, SM
    Dunlop, MG
    [J]. BRITISH JOURNAL OF SURGERY, 2004, 91 (09) : 1231 - 1231
  • [7] IMMUNOTHERAPY AS A MOST WISE THERAPEUTIC APPROACH IN TUMOUR-DERIVED CANCER STEM CELL THERAPY
    Mirzaei, H. R.
    Mirzaei, M.
    [J]. CELLULAR ONCOLOGY, 2010, 32 (03) : 233 - 233
  • [8] Circulating tumour-derived microvesicles in plasma of gastric cancer patients
    Baran, Jaroslaw
    Baj-Krzyworzeka, Monika
    Weglarczyk, Kazimierz
    Szatanek, Rafal
    Zembala, Maria
    Barbasz, Jakub
    Czupryna, Antoni
    Szczepanik, Antoni
    Zembala, Marek
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2010, 59 (06) : 841 - 850
  • [9] Circulating tumour-derived microvesicles in plasma of gastric cancer patients
    Jaroslaw Baran
    Monika Baj-Krzyworzeka
    Kazimierz Weglarczyk
    Rafal Szatanek
    Maria Zembala
    Jakub Barbasz
    Antoni Czupryna
    Antoni Szczepanik
    Marek Zembala
    [J]. Cancer Immunology, Immunotherapy, 2010, 59 : 841 - 850
  • [10] Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings
    Jonasch, E.
    Wood, C.
    Tamboli, P.
    Pagliaro, L. C.
    Tu, S. M.
    Kim, J.
    Srivastava, P.
    Perez, C.
    Isakov, L.
    Tannir, N.
    [J]. BRITISH JOURNAL OF CANCER, 2008, 98 (08) : 1336 - 1341